All In Biotech

Drug Trial Radar · NCT01467713

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

Last checked: Nov 20, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 642 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

642

Actual

Start

Dec 2011

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 9, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of ramelteon, once nightly before bedtime (QHS), sublingual (SL), in the maintenance treatment of Bipolar I Disorder in adult patients.

Conditions

  • Bipolar Disorder

Interventions

  • Ramelteon SLDrug

    Ramelteon sublingual (SL) tablets

  • PlaceboDrug

    Ramelteon sublingual (SL) placebo-matching tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to Any RelapseTime frame: Randomization to Month 12 double-blind treatment period

Locations

156 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Dothan, Alabama

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bellflower, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Garden Grove, California

  • Site not named

    Harbor City, California

  • Site not named

    Huntington Park, California

  • Site not named

    Irvine, California

  • Site not named

    Lomita, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Murrieta, California

  • Site not named

    National City, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    Paramount, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Redondo Beach, California

  • Site not named

    Riverside, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Jose, California

  • Site not named

    San Ramon, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Torrance, California

  • Site not named

    Wildomar, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Norwalk, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Clearwater, Florida

  • Site not named

    Coral Gables, Florida

  • Site not named

    Coral Springs, Florida

  • Site not named

    Edgewater, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Leesburg, Florida

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.